BNT162 Vaccine: all 58 studies that test it

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• A Study of COVID-19 Vaccine(s) in Children and AdultsRecruitingNCT07798648Phase 3
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgeRecruitingNCT07730450Phase 4
• Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant PatientsNot yet recruitingNCT07390968Phase 2
• mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery RoutesNot yet recruitingNCT06919796Phase 2
• Anti-viral Action Against Type 1 Diabetes AutoimmunityRecruitingNCT06452654Phase 4
• A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy AdultsCompletedNCT06237049Phase 2Results posted
• A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy IndividualsCompletedNCT05997290Phase 2/3Results posted
• Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of AgeCompletedNCT05310084Phase 3Results posted
• COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)CompletedNCT05289037Phase 2Results posted
• Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.CompletedNCT05265065Phase 3Results posted
• Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).TerminatedNCT05228730Phase 3Results posted
• Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse ReactionCompletedNCT05212610Phase 4Results posted
• Assessing Immune Response of Different COVID-19 Vaccines in Older AdultsCompletedNCT05160766Phase 2Results posted
• COVID-19 3rd Dose Vaccine in Transplant PatientsTerminatedNCT05047640Phase 3Results posted
• COVID-19 Vaccine Boosters in Patients With CKDTerminatedNCT05022329Phase 2/3Results posted
• Booster Dose TrialTerminatedNCT05016622Phase 2Results posted
• Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy ParticipantsCompletedNCT05004181Phase 2Results posted
• COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.CompletedNCT04955626Phase 3Results posted
• A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial SubjectsCompletedNCT04949490Phase 2Results posted
• Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 YearsCompletedNCT04895982Phase 2Results posted
• Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesCompletedNCT04889209Phase 1/2Results posted
• Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2CompletedNCT04887948Phase 3Results posted
• A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy AdultsCompletedNCT04816669Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenCompletedNCT04816643Phase 3Results posted
• COVID-19 Vaccination of Immunodeficient Persons (COVAXID)CompletedNCT04780659Phase 4Results posted
• COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 VaccinationsCompletedNCT04761822Phase 2Results posted
• To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and OlderCompletedNCT04754594Phase 2/3Results posted
• A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy ParticipantsCompletedNCT04713553Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese AdultsCompletedNCT04588480Phase 4Results posted
• Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy SubjectsCompletedNCT04523571Phase 1Results posted
• A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised AdultsCompletedNCT04380701Phase 1/2Results posted
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsCompletedNCT04368728Phase 2/3Results posted
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeCompletedNCT07300839Phase 3
• A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19CompletedNCT07222384Phase 3
• A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 YearsCompletedNCT07069309Phase 3
• Immunogenicity After COVID-19 Vaccines in Adapted SchedulesCompletedNCT06189040Phase 4
• Intradermal Administration of a COVID-19 mRNA Vaccine in ElderlyTerminatedNCT05977127Phase 2
• COVID-19 Fourth Dose Study in AustraliaWithdrawnNCT05543356Phase 3
• Intradermal Tozinameran for Patients With Immune-mediated Dermatologic DiseasesCompletedNCT05406908Phase 4
• Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)WithdrawnNCT05387317Phase 3
• Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First DoseStatus unknownNCT05378191Phase 2
• Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing TrialCompletedNCT05343871Phase 4
• PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALSStatus unknownNCT05279365Phase 2/3
• Fourth BNT162b2 COVID-19 Vaccine DoseActive, not recruitingNCT05231005Phase 4
• Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection ReductionCompletedNCT05168709Phase 4
• The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 VaccineStatus unknownNCT05132855Phase 1/2
• Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary VaccinationStatus unknownNCT05124171Phase 3
• Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)CompletedNCT05057182Phase 4
• Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)CompletedNCT05057169Phase 4
• IntraDermal Versus Intramuscular Comirnaty® Efficacy StudyWithdrawnNCT05029245Phase 3
• Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine BoosterStatus unknownNCT04992182Phase 2
• Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their SiblingsCompletedNCT04969601Phase 1/2
• Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2Status unknownNCT04907331Phase 2
• Immunocompromised Swiss Cohorts Based Trial PlatformCompletedNCT04805125Phase 3
• Covid-19 Vaccination in Adolescents and ChildrenActive, not recruitingNCT04800133Phase 2
• Antibody Response to COVID-19 Vaccines in Liver Disease PatientsCompletedNCT04775069Phase 4
• Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationCompletedNCT04649021Phase 2

← BNT162 Vaccine overview